Merck (MRK)’s CEO Has a “Better Hand,” Says Jim Cramer

Core Viewpoint - Merck & Co., Inc. (NYSE:MRK) is experiencing a positive shift in its stock performance due to successful drug trials and optimistic analyst ratings, particularly in light of its upcoming patent expirations for Keytruda [2][3]. Group 1: Company Performance - Merck's shares have remained flat year-to-date but saw a positive run starting November 3rd, attributed to successful catalysts [2]. - The company announced successful phase two trials for its heart drug Winrevair on November 18th, allowing it to proceed to phase three studies [2]. - The success of Winrevair is crucial for Merck as it seeks to sustain revenue following the impending patent expirations of its cancer drug Keytruda [2]. Group 2: Analyst Ratings - Bank of America raised Merck's share price target to $120 from $105, maintaining a Buy rating based on new estimates for FY27 EPS [3]. - Morgan Stanley, while reiterating an Equal Weight rating, raised its price target to $102 from $100 [3]. - Jim Cramer expressed optimism about Merck's stock potential, suggesting it has a "better hand" compared to competitors [3].